Clear Street: Gilead Deal Highlights Huge Potential in Cullinan’s Pipeline

Gilead’s up to $2.2B acquisition of Ouro Medicines highlights strong potential for Cullinan Therapeutics’ velinotamig. Clear Street maintains Buy rating with $33 PT.